Amneal Pharmaceuticals Launches Felbamate Oral Suspension

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, LLC is pleased to announce availability of the first generic Felbamate oral suspension in 600 mg/5 mL strength. Amneal’s newest first-to-market product is an AB-rated, therapeutically equivalent alternative to the antiepileptic Felbatol® (a registered trademark of Meda Pharmaceuticals Inc.). Annual U.S. sales of Felbatol® are $17.6 million according to June 2011 IMS Health market data. Amneal received ANDA approval for Felbamate oral suspension from the U.S. FDA on December 16, 2011.